SteelPeak Wealth LLC lessened its position in Astrana Health, Inc. (NASDAQ:ASTH – Free Report) by 3.4% during the 1st quarter, HoldingsChannel.com reports. The fund owned 559,937 shares of the company’s stock after selling 20,000 shares during the quarter. SteelPeak Wealth LLC’s holdings in Astrana Health were worth $13,730,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Signaturefd LLC increased its position in shares of Astrana Health by 57.9% during the fourth quarter. Signaturefd LLC now owns 1,058 shares of the company’s stock worth $26,000 after purchasing an additional 388 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Astrana Health by 144.7% in the 4th quarter. GAMMA Investing LLC now owns 1,473 shares of the company’s stock valued at $37,000 after purchasing an additional 871 shares in the last quarter. Swiss National Bank lifted its holdings in Astrana Health by 1.2% in the 3rd quarter. Swiss National Bank now owns 86,944 shares of the company’s stock valued at $2,465,000 after purchasing an additional 1,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Astrana Health by 5.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company’s stock worth $799,000 after purchasing an additional 1,263 shares during the last quarter. Finally, Deutsche Bank AG boosted its stake in Astrana Health by 3.9% during the 4th quarter. Deutsche Bank AG now owns 41,265 shares of the company’s stock worth $1,024,000 after purchasing an additional 1,550 shares during the last quarter. 52.77% of the stock is owned by institutional investors and hedge funds.
Astrana Health Stock Down 4.1%
Shares of NASDAQ:ASTH opened at $45.10 on Friday. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of 73.93 and a beta of 0.89. Astrana Health, Inc. has a 12-month low of $18.08 and a 12-month high of $51.60. The business has a 50-day moving average price of $41.29 and a 200 day moving average price of $31.15. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 1.20.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the stock. TD Cowen increased their target price on shares of Astrana Health from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday. Needham & Company LLC raised their price target on shares of Astrana Health from $30.00 to $41.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Barclays upgraded shares of Astrana Health from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $37.00 to $50.00 in a research report on Tuesday, May 26th. Weiss Ratings raised shares of Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 1st. Finally, Robert W. Baird set a $45.00 price objective on shares of Astrana Health in a report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $47.86.
Read Our Latest Research Report on ASTH
Astrana Health Profile
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.
Recommended Stories
- Five stocks we like better than Astrana Health
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding ASTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrana Health, Inc. (NASDAQ:ASTH – Free Report).
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.
